Trials / Withdrawn

WithdrawnNCT00463762

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections In Slovakia. An Open, Prospective, Non-Comparative Study.

Status: Withdrawn
Phase: —
Study type: Observational
Enrollment: 0 (actual)

Sponsor: Pfizer · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The primary objective is to collect data on treatment outcomes (clinical and microbiological cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with serious intra-abdominal and hepatobiliary infections in Slovakia.

Conditions

Abscess, Intra-Abdominal
Cholecystitis
Wound Infections
Peritonitis
Appendicitis

Interventions

Type	Name	Description
DRUG	CP-75385-02 Cefoperazone/sulbactam

Timeline

Start date: 2007-05-01
First posted: 2007-04-20
Last updated: 2011-04-22

Source: ClinicalTrials.gov record NCT00463762. Inclusion in this directory is not an endorsement.